Pear Therapeutics Announces Publication of Economic Analysis Assessing the Cost-Effectiveness of reSET-O® in Treating Opioid Use Disorder (OUD)
By
Staff
4 months ago
reSET-O® is the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for patients with opioid use disorder (OUD).
New economic analysis showed reSET-O to be cost-effective compared to treatment-as-usual alone over 12 weeks, and to have economic dominance when contingency management (CM) was included as part of treatment as usual.
BOSTON & SAN FRANCISCO–(BUSINESS WIRE)–Pear Therapeutics, Inc., today announced publication of a new economic analysis describing the cost-effectiveness of reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD). The analysis, “